I disagree I think any company that has a good product tries to hold up and not give out any information until the day they launch an effective marketing campaign before commercialization. They might benefit from rumors to get early adopters interested, but not by directly releasing any significant information without even having completed the clinical trials (since they don't fully know what the true potential of the product is and therefore they may set expectations too high or low and create confusion).
Histogen at the ISHRS conference
Collapse
X
-
-
you know i agree with you. it just dawned on me that they could snap a pic of a full head of hair, then something could go terribly wrong, and they'd have the entire bald world expecting the cure and up in arms when they had to break the bad news.I disagree I think any company that has a good product tries to hold up and not give out any information until the day they launch an effective marketing campaign before commercialization. They might benefit from rumors to get early adopters interested, but not by directly releasing any significant information without even having completed the clinical trials (since they don't fully know what the true potential of the product is and therefore they may set expectations too high or low and create confusion).Comment
-
bingo, definitely could be a reason.
anyway this place needs to be modded, I dont like coming on here to silly fights that go on for two pages.
Keep this site informative and discussion based, let's not turn it into a shouting match.Comment
-
Yes indeed - the value of the company is a function of the value of future sales - so messing things up by releasing too much data ahead of proper productr launch would be a mistake no one in any company wants to make.
I frankly doubt Histogen will be it, but I do think it will be a good weapon if combined with other stuff. We'll find out I guess!
But yeah, let's not expect some groundbreaking revelation at the congress, and let's keep in mind companies attend the number 1 reason why companies attend is business development.
In particular Histogen needs a partner to licence the product to before they can launch it and finish clinical trials (SOURCE)... so in my opinion that is also the news we should look forward to, not so much final phase 2 results (which though may give us an idea of how long HSC effects will last).
I think we all have to wait for phase 3 to have a definitive idea of what to expect from the product...Comment
-
when is the congress?Yes indeed - the value of the company is a function of the value of future sales - so messing things up by releasing too much data ahead of proper productr launch would be a mistake no one in any company wants to make.
But yeah, let's not expect some groundbreaking revelation at the congress, and let's keep in mind companies attend the number 1 reason why companies attend is business development.
i think ur sugarcoating things. the company said they would release pics in feb regardless of what u speculate for its company strategy. by not doing so isnt smart company strategy - it could hurt its reputation.
just to correct u with all due respect, a company's value is not based on the value of its future sales, its based on the value of its expected future sales.. just letting u know.Comment
-
Youre not in any position to make any kind of judgement of what constitutes right or wrong launch strategies. You're not a CEO and going by your comments in the forum, you've got the IQ of a fvcking rock.when is the congress?
i think ur sugarcoating things. the company said they would release pics in feb regardless of what u speculate for its company strategy. by not doing so isnt smart company strategy - it could hurt its reputation.
just to correct u with all due respect, a company's value is not based on the value of its future sales, its based on the value of its expected future sales.. just letting u know.Comment
-
Again - Ziering (an outside consultant for the company) said he planned on having some pictures in February. That is not the same of what you're saying, and everytime I point that out to you, you just start insulting me and the conversation gets stuck with you producing no logical feedback.
The value of the company NOW is based on expected future sales, correct, but the most recent sources show they do not intend to sell before product launch - hence it is correct to just talk about future sales affecting the future value of the company.Comment
-
sounds good.. thanks.Again - Ziering (an outside consultant for the company) said he planned on having some pictures in February. That is not the same of what you're saying, and everytime I point that out to you, you just start insulting me and the conversation gets stuck with you producing no logical feedback.
The value of the company NOW is based on expected future sales, correct, but the most recent sources show they do not intend to sell before product launch - hence it is correct to just talk about future sales affecting the future value of the company.Comment
-
Ziering stated and you could see from some of the 6th month pictures that most if not all vellus hairs should return to terminal, even in the receding hairline.
That one women practically grew her entire hairline back due to having a lot of vellus hairs, but in fairness the other results werent as good as hers(at the 6-7 month mark).
So i'd say it would do alot if you catch the loss early on, later I'm not so sure, and IMO yes a DHT blocker is still needed, but we'll see if that's still the case when they test out more frequent doses.Comment
-
Yes indeed! We all know it's a great weapon already, but IMO those above 15 years old now cannot rely on it solely because it will be released in some years.... I still haven't given up on Aderans, if only one of these alternative companies were able to deliver something within the next 5 years, we'd virtually have results comparable to those of a cure...Comment
Comment